Advertisement

The effect of photodynamic therapy on macular sensitivity in eyes with acute central serous chorioretinopathy

  • Stefan Hagen
  • Siamak Ansari-ShahrezaeiEmail author
  • Eva Smretschnig
  • Carl Glittenberg
  • Ilse Krebs
  • Alexandra Graf
  • Susanne Binder
Retinal Disorders

Abstract

Background

To evaluate the effect of half-fluence rate indocyanine green angiography (ICGA)-guided verteporfin photodynamic therapy (PDT) on macular sensitivity (MS) in eyes with acute symptomatic central serous chorioretinopathy (CSC).

Methods

Single-center consecutive case series by retrospective chart review. Sixteen eyes of 16 patients with acute CSC of 3 months duration or less, treated with half-fluence (25 mJ/cm2) ICGA-guided verteporfin PDT were reviewed. At baseline and after 1, 3, and 6 months, all patients underwent MS testing of the central 20 °, MS testing of the retinal area covered by the PDT laser spot (MSLS), and evaluation of fixation stability (FS) for the central two degrees with the MP-1 microperimeter (Nidek, Vigonza, Italy).

Results

Macular sensitivity improved from 16.4 ± 3.0 dB at baseline (n = 16) to 18.2 ± 2.4 dB (p < 0.001) at 1 month (n = 16). At the 3-month (n = 13) and 6-month (n = 12) follow-up, MS stabilized at 19.5 ± 0.9 dB (p = 0.21) and 19.0 ± 1.3 dB (p = 0.74), without changes when compared to respective precedent follow-up. Mean MSLS improved from 12.9 ± 5.4 dB at baseline to 16.4 ± 4.9 dB (p < 0.001) after 1 month. At the 3- and 6-month follow-up, MSLS was 19.1 ± 1.2 dB (p = 0.1) and 18.9 ± 1.9 dB (p = 0.8) respectively. Mean FS at the central 2 ° was 78.8 ± 30.4 % before treatment and 81.8 ± 29.5 % (p = 0.7), 81.9 ± 27.5 % (p = 0.7) and 83.6 ± 17.1 % (p = 0.5) respectively 1, 3 and 6 months after treatment.

Conclusion

Half-fluence (25 mJ/cm2) PDT significantly increased mean MS of central 20 ° and mean MSLS, in eyes with acute symptomatic CSC. Fixation stability was stable at baseline and throughout 6 months of follow-up.

Keywords

Central serous chorioretinopathy Macular sensitivity Microperimetry Photodynamic therapy 

Notes

Conflicts of interest

The authors have no conflict of interest to declare.

Financial support

No financial support was provided for this study.

References

  1. 1.
    Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D (1994) Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 112:1057–1062PubMedCrossRefGoogle Scholar
  2. 2.
    Gass JD (1967) Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 63(Suppl):1–139PubMedGoogle Scholar
  3. 3.
    Yannuzzi LA (1987) Type-A behavior and central serous chorioretinopathy. Retina 7:111–131PubMedCrossRefGoogle Scholar
  4. 4.
    Loo RH, Scott IU, Flynn HW Jr, Gass JD, Murray TG, Lewis ML, Rosenfeld PJ, Smiddy WE (2002) Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 22:19–24PubMedCrossRefGoogle Scholar
  5. 5.
    Robertson DM (1986) Argon laser photocoagulation treatment in central serous chorioretinopathy. Ophthalmology 93:972–974PubMedGoogle Scholar
  6. 6.
    Pikkel J, Beiran I, Ophir A, Miller B (2002) Acetazolamide for central serous retinopathy. Ophthalmology 109:1723–1725PubMedCrossRefGoogle Scholar
  7. 7.
    Meyerle CB, Freund KB, Bhatnagar P, Shah V, Yannuzzi LA (2007) Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina 27:943–946PubMedCrossRefGoogle Scholar
  8. 8.
    Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM (2003) Photodynamic therapy for chronic central serous chorioretinopathy. Retina 23:752–763PubMedCrossRefGoogle Scholar
  9. 9.
    Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa DL, Huang SJ, Klancnik JM Jr, Aizman A (2003) Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 23:288–298PubMedCrossRefGoogle Scholar
  10. 10.
    Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK (2003) Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 87:1453–1458PubMedCrossRefGoogle Scholar
  11. 11.
    Levine R, Brucker AJ, Robinson F (1989) Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography. Ophthalmology 96:854–859PubMedGoogle Scholar
  12. 12.
    Colucciello M (2006) Choroidal neovascularization complicating photodynamic therapy for central serous retinopathy. Retina 26:239–242PubMedCrossRefGoogle Scholar
  13. 13.
    Chan WM, Lai TY, Lai RY, Liu DT, Lam DS (2008) Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 115:1756–1765PubMedCrossRefGoogle Scholar
  14. 14.
    Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, Sanfilippo M, Russo A, Uva MG, Munno F, Cannemi V, Zagari M, Boscia F (2010) Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 149:307–315PubMedCrossRefGoogle Scholar
  15. 15.
    Chan WM, Lai TY, Lai RY, Tang EW, Liu DT, Lam DS (2008) Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina 28:85–93PubMedCrossRefGoogle Scholar
  16. 16.
    Smretschnig E, Ansari-Shahrezaei S, Moussa S, Glittenberg C, Krebs I, Binder S (2012) Half-fluence photodynamic therapy in acute central serous chorioretinopathy. Retina Mar 29 [Epub ahead of print]Google Scholar
  17. 17.
    Taban M, Boyer DS, Thomas EL, Taban M (2004) Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol 137:1073–1080PubMedCrossRefGoogle Scholar
  18. 18.
    Battaglia Parodi M, Da Pozzo S, Ravalico G (2003) Photodynamic therapy in chronic central serous chorioretinopathy. Retina 23:235–237PubMedCrossRefGoogle Scholar
  19. 19.
    Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS (2006) Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol 90:869–874PubMedCrossRefGoogle Scholar
  20. 20.
    Chen FK, Patel PJ, Xing W, Bunce C, Egan C, Tufail AT, Coffey PJ, Rubin GS, Da Cruz L (2009) Test-retest variability of microperimetry using the Nidek MP1 in patients with macular disease. Invest Ophthalmol Vis Sci 50:3464–3472PubMedCrossRefGoogle Scholar
  21. 21.
    Chen FK, Patel PJ, Webster AR, Coffey PJ, Tufail A, Da Cruz L (2011) Nidek MP1 is able to detect subtle decline in function in inherited and age-related atrophic macular disease with stable visual acuity. Retina 31:371–379PubMedCrossRefGoogle Scholar
  22. 22.
    Roesel M, Heimes B, Heinz C, Henschel A, Spital G, Heiligenhaus A (2011) Comparison of retinal thickness and fundus-related microperimetry with visual acuity in uveitic macular oedema. Acta Ophthalmol 89:533–537PubMedCrossRefGoogle Scholar
  23. 23.
    Ehrlich R, Mawer NP, Mody CH, Brand CS, Squirrell D (2012) Visual function following photodynamic therapy for central serous chorioretinopathy: a comparison of automated macular microperimetry versus best-corrected visual acuity. Clin Experiment Ophthalmol 40:e32–e39PubMedCrossRefGoogle Scholar
  24. 24.
    Ansari-Shahrezaei S, Ergun E, Stur M (2006) The effect of digital measurement software on photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 244:137–142PubMedCrossRefGoogle Scholar
  25. 25.
    Ansari-Shahrezaei S, Binder S, Stur M (2011) The effect of laser unit on photodynamic therapy spot size. Graefes Arch Clin Exp Ophthalmol 249:11–14PubMedCrossRefGoogle Scholar
  26. 26.
    Wu ZH, Lai RY, Yip YW, Chan WM, Lam DS, Lai TY (2011) Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial. Retina 31:1378–1386PubMedCrossRefGoogle Scholar
  27. 27.
    Reibaldi M, Boscia F, Avitabile T, Uva MG, Russo A, Zagari M, Occhipinti F, Russo V, Reibaldi A, Longo A (2011) Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 151:953–960PubMedCrossRefGoogle Scholar
  28. 28.
    Kondo M, Ito Y, Miyata K, Kondo N, Ishikawa K, Terasaki H (2006) Effect of axial length on laser spot size during photodynamic therapy: an experimental study in monkeys. Am J Ophthalmol 141:214–215PubMedCrossRefGoogle Scholar
  29. 29.
    Ansari-Shahrezaei S, Ergun E, Stur M (2006) The effect of axial length on photodynamic therapy. Am J Ophthalmol 141:699–702PubMedCrossRefGoogle Scholar
  30. 30.
    Visudyne in Minimally Classic Choroidal Neovascularization Study Group (2005) Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration.2-year results of a randomized clinical trial. Arch Ophthalmol 123:448–457CrossRefGoogle Scholar
  31. 31.
    Lai TY, Chan WM, Lam DS (2004) Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy. Am J Ophthalmol 137:826–833PubMedCrossRefGoogle Scholar
  32. 32.
    Fujita K, Yuzawa M, Mori R (2011) Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results. Retina 31:772–778PubMedGoogle Scholar
  33. 33.
    Senturk F, Karacorlu M, Ozdemir H, Karacorlu SA, Uysal O (2011) Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol 151:303–309PubMedCrossRefGoogle Scholar
  34. 34.
    Ozdemir H, Senturk F, Karacorlu M, Arf Karacorlu S, Uysal O (2008) Macular sensitivity in eyes with central serous chorioretinopathy. Eur J Ophthalmol 18:799–804PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Stefan Hagen
    • 1
    • 2
  • Siamak Ansari-Shahrezaei
    • 1
    • 2
    • 3
    • 4
    Email author
  • Eva Smretschnig
    • 1
    • 2
  • Carl Glittenberg
    • 1
    • 2
  • Ilse Krebs
    • 1
    • 2
  • Alexandra Graf
    • 5
  • Susanne Binder
    • 1
    • 2
    • 4
  1. 1.The Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery, ViennaWienAustria
  2. 2.Department of OphthalmologyRudolf Foundation Clinic, ViennaWienAustria
  3. 3.Department of OphthalmologyMedical University of Graz, GrazGrazAustria
  4. 4.Retina Center Vienna, ViennaWienAustria
  5. 5.Core Unit for Medical Statistics and InformaticsMedical University of Vienna, ViennaWienAustria

Personalised recommendations